BriaCell Therapeutics (CVE:BCT) Given New C$15.00 Price Target at HC Wainwright

BriaCell Therapeutics (CVE:BCT) had its price objective cut by HC Wainwright from C$18.00 to C$15.00 in a research report report published on Thursday morning, BayStreet.CA reports.

BriaCell Therapeutics Trading Down 3.8 %

BCT stock opened at C$10.60 on Thursday. BriaCell Therapeutics has a 12-month low of C$3.50 and a 12-month high of C$15.75. The business’s 50-day moving average is C$10.60 and its 200 day moving average is C$10.60. The company has a current ratio of 129.63, a quick ratio of 128.68 and a debt-to-equity ratio of 0.05. The stock has a market cap of C$168.68 million and a price-to-earnings ratio of -28.19.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.